
R406
CAS No. 841290-81-1
R406( —— )
Catalog No. M16127 CAS No. 841290-81-1
R406 is a potent Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 50 | In Stock |
![]() ![]() |
5MG | 77 | In Stock |
![]() ![]() |
10MG | 138 | In Stock |
![]() ![]() |
25MG | 300 | In Stock |
![]() ![]() |
50MG | 446 | In Stock |
![]() ![]() |
100MG | 647 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameR406
-
NoteResearch use only, not for human use.
-
Brief DescriptionR406 is a potent Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.
-
DescriptionR406 is a potent Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.
-
In VitroR406 inhibits adenosine A3 receptor (IC50=0.081 μM), adenosine transporter (IC50=1.84 μM), and monoamine transporter (IC50=2.74 μM).R406 inhibits Huh7 hepatocyte, A549 epithelial, and H1299 lung cancer lines with EC50s of 15.1, 2.9 and 6.3 μM, respectively.R406 inhibits phosphorylation of Syk substrate LAT in mast cells and BLNK/SLP65 in B cells. Western Blot AnalysisCell Line:Cultured human mast cells (CHMC)Concentration:0.016, 0.08, 0.4, 2 μM Incubation Time:40 minutes Result:Inhibited all other kinases tested at 5 to 100 fold less potency than Syk as judged by phosphorylation of target proteins.
-
In VivoR406 (5 and 10 mg/kg) shows efficacy in the amelioration of the Arthus reaction and in reducing clinical symptoms in the collagen antibody-induced arthritis (CAIA) and K/BxN models of rheumatoid arthritis (RA). Immune complex (IC)-mediated inflammation is reduced by inhibition of Fc receptor signaling with R406. Animal Model:Female Balb/c mice (6-8 weeks) with CAIADosage:5 and 10 mg/kg Administration:Administered orally, b.i.d, for 14 days, starting 4 hours after antibody challenge on day 0. Result:Reduced inflammation and swelling, and the arthritis progressed more slowly in treated animals than in vehicle controls.Animal Model:Female C57BL/6 mice with arthritis Dosage:10 mg/kg Administration:Administered orally one hour before serum injection; b.i.d; for 13 days Result:Delayed the onset and reduced the severity of clinical arthritis. Paw thickening and clinical arthritis were reduced by approximately 50%.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetSyk
-
RecptorSyk
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number841290-81-1
-
Formula Weight628.63
-
Molecular FormulaC22H23FN6O5·C6H6O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO:126 mg/mL (200.43 mM); Ethanol:8 mg/mL (12.72 mM); Water:<1 mg/mL (<1 mM)
-
SMILESOS(=O)(=O)C1=CC=CC=C1.COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4)C=C3)=N2)=CC(OC)=C1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Braselmann S, et al. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.
molnova catalog



related products
-
OXSI-2
OXSI-2 is an inhibitor of Syk with an EC50 of 313 nM and an IC50 of 14 nM. OXSI-2 completely inhibits Adaptor protein LAT Y191 phosphorylation and Syk mediated events in platelets.
-
SecinH3
SecinH3 is selective cytohesin inhibitor.
-
LM22B-10
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.